{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Table 1', 'CL04041024 (CREDO 4) Schedule of Events (Open-Label Treatment Period and Safety Follow-Up Period)', 'OLE', 'Assessments', 'Open-Label Treatment Period', 'EoT', 'Baseline', 'Safety Follow-Up Period', 'Visit', '1a', '2', '3', '4', '5', '6', '7', '8', '9', '10', 'SFU-1', 'SFU-2', 'SFU-3', 'Week', '24', '26', '28', '36', '44', '52', '64', '76', '88', '106 (+2b)', '108 (+4b)', '112 (+8b)', '126 (+22b)', 'Visit Window (days)', '+5', '5', '+5', '5', '5', '+5', '+5', '+5', '+5', '5', '7', '7', '7', 'Obtain informed consent', 'Determine eligibility for OLE', 'Height', 'Weight', 'Physical examination', 'Vital signsd', 'Contraceptive history/status', 'Concomitant and prior medications/non-drug', 'therapy', 'Randomization', 'Training for study treatment administration', 'Study treatment allocation through IWRS', 'f', 'Administer study treatment', 'i,j', 'f,i,j', 'i,j', 'Study treatment compliance', 'EFFICACY ASSESSMENTS', 'Patient Global Assessment of Disease Activity', '(VAS)', 'Patient Assessment of Pain (VAS)', 'HAQ-DI', 'SF-36, EQ-5D, FACIT-Fatigue, and WPS-RA', 'Joint counts (Independent Joint Assessment)', 'Assessment of nonresponders\u00b9', 'Amendment 2: 06 March 2019', '46', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'OLE', 'Assessments', 'Open-Label Treatment Period', 'EoT', 'Baseline', 'Safety Follow-Up Period', 'Visit', '1a', '2', '3', '4', '5', '6', '7', '8', '9', '10', 'SFU-1', 'SFU-2', 'SFU-3', 'Week', '24', '26', '28', '36', '44', '52', '64', '76', '88', '106 (+2b)', '108 (+4b)', '112 (+8b)', '126 (+22b)', 'Visit Window (days)', '+5', '5', '5', '+5', '5', '5', '5', '+5', '5', '5', '7', '7', '7', 'Physician Global Assessment (VAS)', 'CRP', 'ESR', 'Safety Assessments', 'AEs/SAEs\"', 'IGRAC', 'Pregnancy testP', 'INR, aPTT, fibrinogen\u00b0', 'Lipid panel (fasting)', 'CV risk panels', 'CV risk assessment', 'Hematology\"', 'Chemistry panely', 'HbA1c\" (only for subjects with diabetes', 'mellitus)', 'Urinalysis*', 'PK blood samples', 'y', 'ADAs', 'ANA and anti dsDNA antibody', 'Assess injection site reactions', 'TB risk questionnaire', 'Chest X-ray2', '12-lead ECG', 'Amendment 2: 06 March 2019', '47', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'OLE', 'Assessments', 'Open-Label Treatment Period', 'EoT', 'Baseline', 'Safety Follow-Up Period', 'Visit', '1a', '2', '3', '4', '5', '6', '7', '8', '9', '10', 'SFU-1', 'SFU-2', 'SFU-3', 'Week', '24', '26', '28', '36', '44', '52', '64', '76', '88', '106 (+2b)', '108 (+4b)', '112 (+8b)', '126 (+22b)', 'Visit Window (days)', '+5', '5', '5', '+5', '5', '5', '5', '+5', '5', '5', '7', '7', '7', 'Subject Diary', 'Abbreviations: ADA = antidrug antibody; AEs = adverse events; ALT = alanine aminotransferase; ANA = antinuclear antibody; ApoB = apolipoprotein B;', 'ApoAl = apolipoprotein A1; aPTT = activated partial thromboplastin time; AST = aspartate aminotransferase; BNP = brain natriuretic peptide; BP = blood', 'pressure; CRP = C-reactive protein; CV = cardiovascular; dsDNA = double-stranded DNA; ECG = electrocardiogram; EoT = End of Treatment; EQ-', '5D = European Quality of Life-5 Dimensions; ESR = erythrocyte sedimentation rate; FACIT-Fatigue = Functional Assessment of Chronic Illness', 'Therapy-Fatigue Scale; GGT = gamma-glutamyl transferase; HAQ-DI = Health Assessment Questionnaire-Disability Index; HbA1c = glycosylated hemoglobin;', 'HDL = high-density lipoprotein; IEC = Independent Ethics Committee; IGRA = interferon-gamma release assay; INR = international normalized ratio; IRB =', 'Institutional Review Board; IWRS = Interactive Web Response System; LDL = low-density lipoprotein; NT-proBNP = N-terminal pro-hormone of brain', 'natriuretic peptide; OKZ = olokizumab; OLE = open-label extension; PFS = pre-filled syringe(s) PK = pharmacokinetic(s) PRO = patient-reported outcomes;', 'RBC = red blood count; SAE = serious adverse event; SC = subcutaneous(ly); SF-36 = Short Form-36; SJC = swollen joint count; TB = tuberculosis; TJC =', 'tender joint count; WBC = white blood count; WPS-RA = Work Productivity Survey - Rheumatoid Arthritis; VAS = Visual Analog Scale.', 'a. All subjects will begin the OLE study at Visit 1. The baseline visit for the OLE study is the same visit as the Week 24 visit in the core studies.', 'b. The number of weeks (+2, +4, +8, or +22) after the last dose of the study treatment.', 'c.', 'Complete physical examination should be performed at these visits (Section 7.4.7.1).', 'd.', 'Vital signs include temperature, heart rate, BP, and respiratory rate.', 'e.', 'Subjects (and their caregivers, if applicable) will be trained to administer the study treatment at Visit 1, and the Investigator must observe the first 2', 'administrations (Visits 1 and 2 for subjects receiving OKZ 64 mg q2w or Visits 1 and 3 for subjects receiving OKZ 64 mg q4w) to ensure that proper', 'procedures are followed. This training may be repeated at any visit to the study site if requested by the subject or caregiver,', 'or', 'if', 'deemed', 'appropriate', 'by', 'the Investigator.', 'f.', 'Study treatment allocation and administration at Visit 2 (Week 26) is only for subjects assigned to the OKZ 64 mg q2w treatment', 'group.', 'g.', 'If desired, SC injections may be rotated among the thighs and abdomen.', 'h.', 'Study treatment will be administered every 2 or 4 weeks (according to assigned OKZ treatment regimen) through the last dose of study treatment at', 'Week 104 (not shown on this Schedule of Events).', 'i.', 'Subjects will remain at the study site for at least 2 hours after the first injection of study treatment (Visit 1 [OLE Baseline/Week', '24])', 'and', 'for', 'at', 'least', '30 minutes after the second administration of study treatment (Visit 2 [Week 26] for subjects receiving OKZ 64 mg q2w and Visit 3 [Week 28] for', 'subjects receiving OKZ 64 mg q4w) to be assessed for the onset of any systemic injection reactions (see Section 7.4.3.2 and', 'Appendix', '3', '[Section', '13.3]).', 'j.', 'Administration of study treatment must be observed by the Investigator for the first 2 administrations of OKZ 64 mg q2w (Visit', '1', '[Week', '24]', 'and', 'Visit', '2', '[Week 26]) or OKZ 64 mg q4w (Visit 1 [Week 24] and Visit 3 [Week 28]).', 'k.', 'Starting from Visit 4 (Week 36), subjects must return to the study site eiher all used and unused vials of study treatment or empty cartons of used PFS', 'and unused PFS at each scheduled visit. Compliance will be assessed by the Investigator based on the number of used vials or PFS cartons as', 'applicable.', 'Amendment 2: 06 March 2019', '48', 'Confidential']\n\n###\n\n", "completion": "END"}